Over 400 attendees working within Proteins, Antibodies and Biotherapeutics
Over 40 case studies, presentations and panel discussions
Co-Located with our Biosimilars & Biobetters Congress and Peptides Congress
4 interactive streams:
Antibody Discovery & Development
Protein Purification, Expression & Characterisation
14 pre-scheduled one to one meetings, exhibition and informal networking opportunities
Oxford Global Conferences are proud to present the 7th Annual Proteins & Antibodies Congress, taking place on 3rd & 4th April 2014 at the Novotel London West, UK.
Over two days, this meeting will bring together over 400 senior-level decision makers working at the forefront of the proteins and antibodies field in Europe and the US. The conference programme consists of world-class keynote addresses, industry and academic led presentations and panel debates, creating an interactive platform for high-level scientific and business discussion.
Our panel of Antibody experts will discuss the latest antibody discovery targets and development platforms. Day Two will feature case studies on increasing clinical success rate and the latest insights into armed antibodies and antibody-cytokine fusions.
The Protein Purification, Expression & Characterisation stream will explore the critical issues in protein crystallisation, assays, protein folding and cell line selection.
The Biotherapeutics Optimisation stream will explore the areas of alternative scaffolds and targeted delivery. Our internationally renowned speakers will discuss overcoming the challenges of immunogenicity and aggregation and debate the future of biopharmaceutical development.
• Martin Bader
Head of Protein Chemistry, Roche
• Caroline Barelle
Research Director VNRA Development, University of Aberdeen
• Andreas Baumann
Director, Principal Scientific Expert Biologics, Bayer
• Simon Brack
Director Discovery Research, Covagen
• Steven Coats
Senior Director R&D, MedImmune
• Gerhardus de Jong
Professor Biomolecular Analysis, Ultrecht University
• Rakesh Dixit
VP R&D Head Biologics Safety Assessment, MedImmune
• Claire Dobson
Associate Director, Antibody Discovery & Protein Engineering, MedImmune
• William Finlay
Director Protein Discovery and Optimisation, Global Biotherapeutics Director, Pfizer
• Patrick Garidel
Head of Biopharmaceutical Basic Development, Boehringer Ingelheim